Shanghai MicuRx Pharmaceutical Future Growth
Future criteria checks 2/6
Shanghai MicuRx Pharmaceutical is forecast to grow earnings and revenue by 25.6% and 40% per annum respectively. EPS is expected to grow by 25.2% per annum. Return on equity is forecast to be -230.6% in 3 years.
Key information
25.6%
Earnings growth rate
25.2%
EPS growth rate
| Biotechs earnings growth | 43.4% |
| Revenue growth rate | 40.0% |
| Future return on equity | -230.6% |
| Analyst coverage | Low |
| Last updated | 05 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 397 | -234 | N/A | -244 | 1 |
| 12/31/2025 | 251 | -354 | N/A | -364 | 1 |
| 12/31/2024 | 156 | -399 | N/A | -420 | 1 |
| 9/30/2024 | 120 | -468 | -399 | -398 | N/A |
| 6/30/2024 | 109 | -497 | -428 | -426 | N/A |
| 3/31/2024 | 107 | -467 | -382 | -378 | N/A |
| 12/31/2023 | 91 | -421 | -337 | -329 | N/A |
| 9/30/2023 | 82 | -291 | -295 | -286 | N/A |
| 6/30/2023 | 70 | -238 | -294 | -280 | N/A |
| 3/31/2023 | 55 | -225 | -247 | -233 | N/A |
| 12/31/2022 | 48 | -220 | -252 | -240 | N/A |
| 9/30/2022 | 37 | -275 | -256 | -233 | N/A |
| 6/30/2022 | 28 | -247 | -205 | -181 | N/A |
| 3/31/2022 | 18 | -242 | -218 | -196 | N/A |
| 12/31/2021 | 8 | -226 | -204 | -181 | N/A |
| 12/31/2020 | N/A | -86 | -90 | -89 | N/A |
| 12/31/2019 | N/A | -115 | -112 | -112 | N/A |
| 12/31/2018 | 1 | -150 | -155 | -149 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688373 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688373 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688373 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688373's revenue (40% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688373's revenue (40% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688373 is forecast to be unprofitable in 3 years.